Uptake of an Omega-3 Oil in Healthy Adults

Investigation of Uptake of Two Different Omega-3 Fatty Acid Products in Healthy Subjects - a Randomized, Two-way Cross-over Study

The goal of this clinical trial is to compare the uptake of two different omega-3 fatty acid preparations in healthy adults. The main question it aims to answer is whether the two different preparations have the same uptake after single dose supplementation.

Study Overview

• Status: Completed
• Conditions: Pharmacokinetics; Absorption
• Intervention / Treatment: Dietary supplement: PL+ omega 3 fatty acids; Dietary supplement: FO EE fatty acids

Detailed Description

Participants will be asked to take capsules of the new "phospholipids+" (PL+) omega-3 product (a combination product of krill oil and fish oil) in the morning with a low-fat breakfast. This product contains around 1250 mg eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA).

Researchers will compare this group with another group that takes standard fish oil (FO) ethyl esters (EE, with the same amount of EPA+DHA) to see if there are differences in pharmacokinetic parameters, including incremental area under the curve (iAUC), the maximum concentration of (Cmax) and the time it takes for EPA, DHA and EPA+DHA to reach the maximum concentration (Tmax) in plasma.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Esslingen, Germany
    • BioTeSys GmbH

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy males or females (1:1) aged 18 - 65 years
• Capable and willing to give written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
• Have a low habitual consumption of fatty fish and seafood, defined as a frequency of twice per month or less
• No fish consumption at least two weeks prior to screening visit
• Omega-3 index (≤ 7 %)
• Non-smoker
• BMI: 18 to 32 kg/m2

Exclusion Criteria:

• Omega-3 supplementation history within the last 4 weeks
• Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases, i.e., diabetes, cardiovascular, pulmonary, hematologic, gastrointestinal, neurological, or infectious diseases which could confound the results of the study or put the subject at undue risk
• Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 365 days prior to baseline
• Pregnancy, breast feeding or intention to become pregnant during the study (a pregnancy test will be conducted during screening and visits 1-2)

• General Safety & Laboratory Exclusion Criteria. Patients will be excluded from the study based on the following criteria:

  • Haemoglobin: < 12.0 g/dL (women); < 13.5 g/dL (men)
  • Platelets: < 150 x 103/μL
  • Leukocytes < 4,4 x 103/mm3
  • Aspartate transaminase (AST) or alanine transaminase (ALT) within the normal range
  • Serum creatine within the normal range
  • or further for this study clinically relevant abnormal laboratory findings at screening
• Significant changes in lifestyle or medication (within last 2 months)
• Chronic intake of substances affecting blood coagulation (e.g. acetylic acid, anticoagulants (e.g. Marcumar), diuretics, thiazides), which in the investigator's opinion would impact subject safety
• Difficulty swallowing capsules or predicted inability to swallow the study products
• Individuals who have made a blood donation in excess of 500 mL or who had excess blood loss within the 4 months before the study starts
• Individuals who are currently enrolled in an ongoing clinical trial or who have been an active participant in a clinical trial within the last 4 weeks
• A known allergy or hypersensitivity to any of the ingredients of the study products
• Not willing to abstain from fish consumption or foods/oils high in omega-3 fatty acids
• Subjects considered inappropriate for the study by investigators, including subjects who are unable or unwilling to show compliance with the protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Active group; This group will receive a single dose of the PL+ omega 3 fatty acids capsules first, then receive a single dose of the standard FO EE omega 3 fatty acids capsules. Wash-out period is 2 weeks between treatments.	Dietary supplement: PL+ omega 3 fatty acids; PL+ omega 3 fatty acids is a food supplement that combines krill oil and FO EE. The dose will be around 1250 mg EPA+DHA.; Dietary supplement: FO EE fatty acids; A conventional fish oil food supplement containing EPA and DHA in the EE form. The dose will be 1250 mg EPA+DHA.
Placebo Comparator: Placebo group; This group will receive a single dose of the standard FO EE omega 3 fatty acids capsules first, then receive a single dose of the PL+ omega 3 fatty acids capsules. Wash-out period is 2 weeks between treatments.	Dietary supplement: PL+ omega 3 fatty acids; PL+ omega 3 fatty acids is a food supplement that combines krill oil and FO EE. The dose will be around 1250 mg EPA+DHA.; Dietary supplement: FO EE fatty acids; A conventional fish oil food supplement containing EPA and DHA in the EE form. The dose will be 1250 mg EPA+DHA.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of iAUC of EPA+DHA from 0 to 12 hours (iAUC0-12h) between two study products	Blood concentrations of EPA + DHA in plasma at 0h and 12h will be analyzed, and determination of iAUC0-12h will be calculated. After getting the iAUC0-12h, difference of AUC curves between groups will be calculated. The time point 0h is defined as the time when study subjects is taking the supplement, while time point 12h is defined as 12 hours after the intake of supplement.	0h-12h (on Day 1 and Day 15)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of iAUC of EPA+DHA from 0 to 24hours (iAUC0-24h) between two study products	Blood concentrations for EPA+DHA in plasma at 0h and 24h will be analyzed, and iAUC0-24h will be calculated. After getting the iAUC0-24h, difference of AUC curves between groups will be calculated. The time point 0h is defined as the time when study subjects is taking the supplement, while time point 24h is defined as 24 hours after the intake of supplement.	0h-24h (on Day 2 and Day 16)
Comparison of iAUC EPA+DHA from 0 to 72hours (iAUC0-72h) between two study products	Blood concentrations for EPA+DHA in plasma at 0h and 72h will be analyzed, and iAUC0-72h will be calculated. After getting the iAUC0-72h, difference of AUC curves between groups will be calculated. The time point 0h is defined as the time when study subjects is taking the supplement, while time point 72h is defined as 72 hours after the intake of supplement.	0h-72h (on Day 4 and Day 18)
Comparison of iAUC EPA from 0 to 12hours (iAUC0-12h) between two study products	Blood concentrations for EPA in plasma at 0h and 12h will be analyzed, and iAUC0-12h will be calculated. After getting the iAUC0-12h, difference of AUC curves between groups will be calculated. The time point 0h is defined as the time when study subjects is taking the supplement, while time point 12h is defined as 12 hours after the intake of supplement.	0h-12h (on Day 1 and Day 15)
Comparison of iAUC DHA from 0 to 12hours (iAUC0-12h) between two study products	Blood concentrations for DHA in plasma at 0h and 12h will be analyzed, and iAUC0-12h will be calculated. After getting the iAUC0-12h, difference of AUC curves between groups will be calculated. The time point 0h is defined as the time when study subjects is taking the supplement, while time point 12h is defined as 12 hours after the intake of supplement.	0h-12h (on Day 1 and Day 15)
Comparison of iAUC EPA from 0 to 24hours (iAUC0-24h) between two study products	Blood concentrations for EPA in plasma at 0h and 24h will be analyzed, and iAUC0-24h will be calculated. After getting the iAUC0-24h, difference of AUC curves between groups will be calculated. The time point 0h is defined as the time when study subjects is taking the supplement, while time point 24h is defined as 24 hours after the intake of supplement.	0h-24h (on Day 2 and Day 16)
Comparison of iAUC DHA from 0 to 24hours (iAUC0-24h) between two study products	Blood concentrations for DHA in plasma at 0h and 24h will be analyzed, and iAUC0-24h will be calculated. After getting the iAUC0-24h, difference of AUC curves between groups will be calculated. The time point 0h is defined as the time when study subjects is taking the supplement, while time point 24h is defined as 24 hours after the intake of supplement.	0h-24h (on Day 2 and Day 16)
Comparison of iAUC EPA from 0 to 72hours (iAUC0-72h) between two study products	Blood concentrations for EPA in plasma at 0h and 72h will be analyzed, and iAUC0-72h will be calculated. After getting the iAUC0-72h, difference of AUC curves between groups will be calculated. The time point 0h is defined as the time when study subjects is taking the supplement, while time point 72h is defined as 72 hours after the intake of supplement.	0h-72h (on Day 4 and Day 18)
Comparison of iAUC DHA from 0 to 72hours (iAUC0-72h) between two study products	Blood concentrations for DHA in plasma at 0h and 72h will be analyzed, and iAUC0-72h will be calculated. After getting the iAUC0-72h, difference of AUC curves between groups will be calculated. The time point 0h is defined as the time when study subjects is taking the supplement, while time point 72h is defined as 72 hours after the intake of supplement.	0h-72h (on Day 4 and Day 18)
Difference on Cmax of EPA+DHA between two products	Cmax of EPA+DHA will be calculated for both products, and the difference will be compared between the products.	Day 1 and Day 15
Difference on Cmax of EPA between two products	Cmax of EPA will be calculated for both products, and the difference will be compared between the products.	Day 1 and Day 15
Difference on Cmax of DHA between two products	Cmax of DHA will be calculated for both products, and the difference will be compared between the products.	Day 1 and Day 15
Difference on Tmax of EPA+DHA between two products	Tmax of EPA+DHA will be calculated for both products, and the difference will be compared between the products.	Day 1 and Day 15
Difference on Tmax of EPA between two products	Tmax of EPA will be calculated for both products, and the difference will be compared between the products.	Day 1 and Day 15
Difference on Tmax of DHA between two products	Tmax of DHA will be calculated for both products, and the difference will be compared between the products.	Day 1 and Day 15
Difference on total omega 6 fatty acids vs total omega 3 fatty acid ratio (n-6/n-3) in plasma at 12 hours between two products	Total omega 6 fatty acids include: linoleic acid, γ-Linolenic acid, eicosadienoic acid, eicosatrienoic acid, arachidonic acid, adrenic acid, and docosapentaenoic acid. Total omega 3 fatty acids include: α-Linolenic acid, EPA, docosapentaenoate acid and DHA. The difference on n-6/n-3 ratio will be calculated between two products. The time point 12h is defined as 12 hours after the intake of supplement.	Day 1 and Day 15
Difference on total omega 6 fatty acids vs total omega 3 fatty acid ratio (n-6/n-3) in plasma at 24 hours between two products	Total omega 6 fatty acids include: linoleic acid, γ-Linolenic acid, eicosadienoic acid, eicosatrienoic acid, arachidonic acid, adrenic acid, and docosapentaenoic acid. Total omega 3 fatty acids include: α-Linolenic acid, EPA, docosapentaenoate acid and DHA. The difference on n-6/n-3 ratio will be calculated between two products. The time point 24h is defined as 24 hours after the intake of supplement.	Day 2 and Day 16
Difference on total omega 6 fatty acids vs total omega 3 fatty acid ratio (n-6/n-3) in plasma at 72 hours between two products	Total omega 6 fatty acids include: linoleic acid, γ-Linolenic acid, eicosadienoic acid, eicosatrienoic acid, arachidonic acid, adrenic acid, and docosapentaenoic acid. Total omega 3 fatty acids include: α-Linolenic acid, EPA, docosapentaenoate acid and DHA. The difference on n-6/n-3 ratio will be calculated between two products. The time point 72h is defined as 72 hours after the intake of supplement.	Day 4 and Day 18

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with treatment-related adverse events (AE) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0	During the study period, any changes in physical conditions will be evaluated by investigator using CTCAE v4.0 criteria and will be recorded as AEs or serious adverse events (SAEs). Number of participants with treatment-related AEs and SAEs will be reported to sponsor listed in the study report.	Day 1 to Day 3 and Day 15 to Day 18
Number of participants with abnormal blood routine parameters as assessed by clinical reference values	During the study, blood samples from 2h sample time point will be used for safety check. The following parameters will be assessed: AST, ALT, gammaglutamyltransferase, alkaline phosphatase, total cholesterol, low-density lipoprotein- and high-density lipoprotein-cholesterol, triglycerides; creatinine and uric acid. Participants with abnormal values of any of the above-mentioned parameters that fall out of the clinical reference range will be listed and reported.	Day 1 and Day 15

Collaborators and Investigators

• Sponsor: Aker Biomarine Antarctic AS
• Collaborators: BioTeSys GmbH
• Investigators: Principal Investigator: Daniel Menzel, BioTeSys GmbH

Study record dates

Study Major Dates

• Study Start (Actual): January 9, 2023
• Primary Completion (Actual): February 17, 2023
• Study Completion (Actual): February 17, 2023

Study Registration Dates

• First Submitted: November 24, 2022
• First Submitted That Met QC Criteria: December 6, 2022
• First Posted (Actual): December 14, 2022

Study Record Updates

• Last Update Posted (Actual): March 2, 2023
• Last Update Submitted That Met QC Criteria: March 1, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Keywords: DHA; Omega 3 fatty acids; EPA
• Other Study ID Numbers: BTS1879/22 // AKBM188H

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Data will not be shared

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No